ARTICLE | Clinical News
Tolenix: Additional Phase II data
March 25, 2013 7:00 AM UTC
Additional data from a double-blind, crossover, international Phase II trial in 138 patients showed that twice-daily Tolenix (2 mg tolterodine plus 9 mg pilocarpine) led to a 0.88 reduction in daily u...